Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Completed 2Active not recruiting 2

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 39Gastrointestinal 24Breast 13Dermatologic 10Thoracic 9Head & Neck 9Tumor-Agnostic 8Gynecologic 8Lymphoid 7Sarcoma 6Endocrine 6CNS 6Other hematologic neoplasm 5Other solid neoplasm 4NET 4

Conditions

Neuroendocrine Tumors 4Carcinoma, Merkel Cell 2Neoplasms 1Carcinoma, Neuroendocrine 1Carcinoma 1

Interventions

lutetium Lu 177 dotatate 32Everolimus 19Magnetic Resonance Spectroscopy 14gallium Ga 68 dotatate 12Temozolomide 12Nivolumab 11Capecitabine 10pembrolizumab 9lanreotide 9cabozantinib 8Positron Emission Tomography Computed Tomography 8177Lu-octreotide, DOTA(0)-Tyr(3)- 8Ga(III)-DOTATOC 73-Iodobenzylguanidine 7Somatostatin 6Octreotide 6Lutetium-177 6Carboplatin 690Y-octreotide, DOTA-Tyr(3)- 6telotristat ethyl 5surufatinib 5lenvatinib 5Ipilimumab 5Fluorodeoxyglucose F18 5pasireotide 4copper dotatate CU-64 4avelumab 4Single Photon Emission Computed Tomography Computed Tomography 4Positron-Emission Tomography 4Bevacizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × avelumab × NET × Clear all
NCT04291885 2026-04-09

I-MAT

Melanoma and Skin Cancer Trials Limited

Phase 2 Active not recruiting
122 enrolled
DermatologicEndocrineNET

Carcinoma, Merkel Cell, Neuroendocrine Tumors

NCT04261855 2026-03-27

GoTHAM

Melanoma and Skin Cancer Trials Limited

Phase 1/2 Active not recruiting
19 enrolled
DermatologicEndocrineNET

Carcinoma, Carcinoma, Merkel Cell, Neuroendocrine Tumors

NCT03278379 2024-12-24

NET-002

Sunnybrook Health Sciences Centre

Phase 2 Completed
17 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT03352934 2022-02-25

AveNEC

Johannes Gutenberg University Mainz

Phase 2 Completed
60 enrolled
EndocrineNET

Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡